What's in Mesoblast, Inc.'s pipeline?

Mesoblast, Inc. has 4 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Mesoblast, Inc.'s portfolio?

Top competitors by shared drug class: Ain Shams Maternity Hospital, Aivita Biomedical, Inc., EHL Bio Co., Ltd., Gary A Levy, O. Ont. MD. FRCP AGAF, Gwo Xi Stem Cell Applied Technology Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mesoblast-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

Mesoblast, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesoblast, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Standard of Care for GVHD	Standard of Care for GVHD	phase 3	Mesenchymal stem cell therapy		Immunology
Prochymal®	Prochymal®	phase 3	Stem cell therapy		Immunology

Therapeutic area mix

Immunology · 2
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams Maternity Hospital · 1 shared drug class
Aivita Biomedical, Inc. · 1 shared drug class
EHL Bio Co., Ltd. · 1 shared drug class
Gary A Levy, O. Ont. MD. FRCP AGAF · 1 shared drug class
Gwo Xi Stem Cell Applied Technology Co., Ltd. · 1 shared drug class
Manipal Acunova Ltd. · 1 shared drug class
Nature Cell Co. Ltd. · 1 shared drug class
Tigenix S.A.U. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mesoblast, Inc.:

Cite this brief

Drug Landscape (2026). Mesoblast, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mesoblast-inc. Accessed 2026-06-09.